Veracyte Inc (VCYT) Stock AnalysisVCYTStock AnalysisVeracyte Inc

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Veracyte Inc is currently priced at $43.34, with a forward P/E of 25, indicating potential for growth. However, the RSI is at 46.718, suggesting it is neither overbought nor oversold. The recent earnings report showed a revenue increase of 15% year-over-year, but the stock dropped 22.52% after the earnings announcement, indicating market volatility and uncertainty. The main risk is the lowered full-year testing volume expectations, which could impact future growth.

6 analysts cover VCYT: 4 rate it Buy, 2 Hold and 0 Sell. The average price target is 46.25.